Supernus Pharmaceuticals Inc (SUPN) Holdings Lifted by Cornerstone Capital Management Holdings LLC.

Cornerstone Capital Management Holdings LLC. grew its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 121.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,000 shares of the specialty pharmaceutical company’s stock after buying an additional 59,800 shares during the quarter. Cornerstone Capital Management Holdings LLC. owned approximately 0.21% of Supernus Pharmaceuticals worth $4,360,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 2,220 shares during the period. Riverhead Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 1,462 shares during the period. Advisor Group Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 410 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares during the period. Finally, Flinton Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 88.9% during the second quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after purchasing an additional 2,240 shares during the period. Institutional investors own 98.34% of the company’s stock.

Several research firms recently commented on SUPN. Piper Jaffray Companies restated a “hold” rating and set a $41.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. Cantor Fitzgerald restated a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Jefferies Group restated a “buy” rating and set a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Cowen restated a “buy” rating and set a $50.00 price target on shares of Supernus Pharmaceuticals in a report on Thursday, September 21st. Finally, B. Riley restated a “buy” rating and set a $50.00 price target (down from $53.00) on shares of Supernus Pharmaceuticals in a report on Monday, November 6th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $49.60.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $39.65 on Friday. The firm has a market cap of $2,090.00, a P/E ratio of 36.42, a P/E/G ratio of 1.63 and a beta of 1.19. Supernus Pharmaceuticals Inc has a 52-week low of $23.10 and a 52-week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company’s revenue was up 41.5% on a year-over-year basis. equities analysts predict that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current fiscal year.

WARNING: “Supernus Pharmaceuticals Inc (SUPN) Holdings Lifted by Cornerstone Capital Management Holdings LLC.” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/17/supernus-pharmaceuticals-inc-supn-holdings-lifted-by-cornerstone-capital-management-holdings-llc.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply